{
  "url": "https://openlegislation.uk/eu-regulation-2010-1238/annex-IV",
  "json_url": "https://openlegislation.uk/eu-regulation-2010-1238/annex-IV.json",
  "legislation": "eur/2010/1238",
  "legislation_title": "Regulation (EU) No 1238/2010 of the European Parliament and of the Council of 15 December 2010 amending Annex I to Council Regulation (EEC) No 2658/87 as regards the provision of duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2010-1238",
  "path": "annex/IV",
  "kind": "annex",
  "number": "IV",
  "heading": null,
  "text": "List of pharmaceutical intermediates, i.e. compounds used for the manufacture of finished pharmaceutical products, to be withdrawn from the list of products receiving duty-free treatment included in Annex 6 to Annex I to Regulation (EEC) No 2658/87 due to their transfer to the list of products receiving duty-free treatment included in Annex 3 to Annex I to Regulation (EEC) No 2658/87\nCN code\nCAS RN\nName\n2915 39 00\n2937 29 00\n7753-60-8\n17-alpha-hydroxy-3,20-dioxopregna-4,9(11)-diene-21-yl acetate\nsee anecortave (INN)\n2920 90 85\n163133-43-5\n4-(nitrooxy)butyl (2S)-2-(6-methoxy-2-naphthyl) propanoate\nsee naproxcinod (INN)\n2924 29 98\n194085-75-1\n2-(2-chlorophenyl)-2-hydroxyethyl carbamate\nsee carisbamate (INN)\n2933 39 99\n103129-82-4\n3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate\nsee levamlodipine (INN)\n2933 39 99\n319460-85-0\nN-methyl-2-{[3-((E)-2-pyridin-2-ylvinyl)-1H-indazol-6-yl]sulfanyl}benzamide\nsee axitinib (INN)\n2934 10 00\n302962-49-8\nN-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)thiazole-5-carboxamide\nsee dasatinib (INN)\n2934 99 90\n143491-57-0\n(2R,5S)-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one\nsee emtricitabine(INN)\n2934 99 90\n98819-76-2\n(2S)-2-[(S)-(2-ethoxyphenoxy)phenylmethyl]morpholine\nsee esreboxetine (INN)\n2934 99 90\n475479-34-6\n(2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid\nsee aleglitazar (INN)\n2934 99 90\n377727-87-2\n2-(2-furyl)-7-(2-{4-[4-(2-methoxyethoxy)phenyl] piperazin-1-yl}ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[2,3-c]pyrimidin-5-amine\nsee preladenant (INN)\n2934 99 90\n189003-92-7\n2-{7-fluoro-2-oxo-4-[2-(4-thieno[3,2-c]pyridin-4-ylpiperazin-1-yl)ethyl]quinolin-1(2H)-yl}acetamide\nsee trelanserin (INN)\n2934 99 90\n134379-77-4\n4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1H)-one\nsee dexelvucitabine (INN)\n2934 99 90\n518048-05-0\npotassium 4-[N-(2-fluorobenzyl)carbamoyl]-1-methyl-2-[1-methyl-1-(5-methyl-1,3,4-oxadiazole-2-carboxamido)ethyl]-6-oxo-1,6-dihydropyrimidine-5-olate\nsee raltegravir (INN)\n2935 00 90\n170569-88-7\n4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzene-1-sulfonamide\nsee mavacoxib (INN)\n2935 00 90\n186497-07-4\nN-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide\nsee zibotentan (INN)",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2010/1238/annex/IV",
    "retrieved_at": "2026-11-01T14:50:24.898101+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}